Page last updated: 2024-10-26

dipyridamole and Deficiency, Glucosephosphatase

dipyridamole has been researched along with Deficiency, Glucosephosphatase in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research Excerpts

ExcerptRelevanceReference
"Hemolysis is a frequent adverse effect of ribavirin (RBV)."9.11Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004)
"Hemolysis is a frequent adverse effect of ribavirin (RBV)."5.11Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Grattagliano, I1
Russmann, S1
Palmieri, VO1
Jüni, P1
Bihl, F1
Portincasa, P1
Palasciano, G1
Lauterburg, BH1

Trials

1 trial available for dipyridamole and Deficiency, Glucosephosphatase

ArticleYear
Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
    Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:5

    Topics: Adult; Antiviral Agents; Cell Membrane; Dipyridamole; Erythrocytes; Female; Glutathione; Glutathione

2004